These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2876445)

  • 1. Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics.
    Delini-Stula A
    Pharmacopsychiatry; 1986 Jul; 19(4):134-9. PubMed ID: 2876445
    [No Abstract]   [Full Text] [Related]  

  • 2. [Role of dopamine receptors in the mechanism of action of neuroleptics].
    Lavretskaia EF; Kats MM; Baldenkov GN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):431-5. PubMed ID: 2859724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
    Sokoloff P; Giros B; Martres MP; Bouthenet ML; Schwartz JC
    Nature; 1990 Sep; 347(6289):146-51. PubMed ID: 1975644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain.
    Kanba S; Yagi G; Oguchi E; Nakaki T; Kato R; Richelson E
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):133-4. PubMed ID: 1684393
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term effects of neuroleptics.
    Adv Biochem Psychopharmacol; 1980; 24():1-607. PubMed ID: 6105766
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
    Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An automated method for the assessment of spontaneous and stereotyped climbing behavior in mice. Effects of the selective D1- and D2-dopamine receptor agonists SKF-38393 and RU-24926 and their association.
    Simon P; Charpentier S; Costentin J
    Methods Find Exp Clin Pharmacol; 1991 Mar; 13(2):99-104. PubMed ID: 1830125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug effects on pre- and postsynaptic dopamine receptors.
    Andén NE; Grabowska-Andén M
    Adv Biochem Psychopharmacol; 1980; 24():57-64. PubMed ID: 6105802
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390.
    Hess EJ; Creese I
    Psychopharmacol Bull; 1986; 22(3):605-12. PubMed ID: 2879304
    [No Abstract]   [Full Text] [Related]  

  • 13. D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications.
    Clark D; White FJ
    Synapse; 1987; 1(4):347-88. PubMed ID: 2971273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic activity of the 5-aryltetrahydro-gamma-carboline series. Conformational requirements for interaction with central dopamine receptors.
    Harbert CA; Plattner JJ; Welch WM; Weissman A; Koe BK
    Mol Pharmacol; 1980 Jan; 17(1):38-42. PubMed ID: 6104285
    [No Abstract]   [Full Text] [Related]  

  • 15. Adaptational phenomena in neuroleptic treatment.
    Nielsen IM; Christensen AV; Hyttel J
    Adv Biochem Psychopharmacol; 1978; 19():267-74. PubMed ID: 29449
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of D1 and D2 dopamine antagonists on heroin-trained drug discrimination.
    Corrigall WA; Coen KM
    NIDA Res Monogr; 1989; 95():499. PubMed ID: 2577048
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [How do clozapine and co. work? Pharmacologic mechanisms of atypical neuroleptics].
    Müller WE
    Pharm Unserer Zeit; 2002; 31(6):537-45. PubMed ID: 12481511
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.